Market News & Trends
CiToxLAB Increases Inhalation Test Capabilities
CiToxLAB recently announced it has increased its inhalation test capabilities in North America and Europe. The demand for studies to assess the safety of pharmaceuticals…
Lipid Therapeutics Licenses European Rights to its Lead Product
Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, recently announced they have entered into a…
Mersana Therapeutics Strikes $270 Million Antibody-Drug Conjugate Deal
Mersana Therapeutics, Inc. recently announced it has entered into a collaboration agreement with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology…
Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics' Delivery Technology
Particle Sciences, Inc. (PSI) and Lyotropics Therapeutics, Inc. recently announced PSI has acquired the exclusive rights to the Lyotropics' LyoCell patent portfolio. The LyoCell technology allows…
Study Establishes XMetA as the First Allosteric Insulin Receptor-Activating Antibody to Improve Glycemic Control In Vivo
XOMA Corporation recently announced its study of XMetA, the company's fully human allosteric monoclonal antibody to the insulin receptor, is available online and will be…
Neuronex Announces $100-Million Merger Agreement
Neuronex recently announced the signing of a merger agreement with Acorda Therapeutics that, if completed, would result in full acquisition by Acorda and potential payments…
3/6/2012
Avanir & Concert Announce Exclusive License Agreement Avanir Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. recently announced they have entered into an exclusive license agreement that…
Absorption Systems' Innovation Rewarded With New US Patent for CellPort Technologies
Absorption Systems recently announced a new US patent issued on January 31 that protects intellectual property around its P-glycoprotein (P-gp) knockdown cell line within the…
Aptar Unveils Innovative Delivery Devices for the Future
Aptar Pharma, a world leader in the development and manufacturing of nasal and pulmonary drug delivery devices, recently announced it had presented its latest innovation,…
Avanir & Concert Announce Exclusive License Agreement
Avanir Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. recently announced they have entered into an exclusive license agreement that provides Avanir worldwide rights to develop and…
Haselmeier Establishes New Pen Injector Assembly Facility
Haselmeier, a leading designer and manufacturer of pen injection systems, recently announced it will establish a new manufacturing facility in Bangalore, India, to produce and…
2/21/2012
Catalent Pharma Solutions & NewMarket Sign Development Agreement Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC recently announced they have entered into an agreement to jointly…
Catalent Pharma Solutions & NewMarket Sign Development Agreement
Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC recently announced they have entered into an agreement to jointly formulate and develop a portfolio of products for…
Curis & Debiopharm Announce Initiation of Phase Ib Expansion Study
Curis, Inc. and Debiopharm Group recently announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90)…
DARA BioSciences Signs Exclusive Agreement With Uman Pharma
DARA BioSciences, Inc. recently announced it entered into an exclusive US agreement with Uman Pharma Inc. for commercial rights to gemcitabine, DARA's second newly licensed…
IntelGenx Announces License Agreement With Edgemont Pharmaceuticals
IntelGenx Corp. recently announced it has entered into an exclusive agreement with Edgemont Pharmaceuticals, LLC for the commercialization of IntelGenx's lead product CPI-300 in US.…
Malvern & Postnova to Deliver Solution for Characterizing Challenging Particulate Systems
Malvern Instruments and Postnova Analytics recently announced they are co-operating to deliver the combined FFF (Field-Flow Fractionation) and DLS (Dynamic Light Scattering) solutions that today…
Sandoz Buys Rights to Apricus Biosciences' Drug for $28 Million
Apricus Biosciences, Inc. recently announced its wholly owned subsidiary NexMed, Inc. has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to…
2/14/2012
Bend Research Signs License Agreement With Eli Lilly & Company Bend Research Inc., a leading independent drug formulation development and manufacturing company, recently announced it…
Bend Research Signs License Agreement With Eli Lilly & Company
Bend Research Inc., a leading independent drug formulation development and manufacturing company, recently announced it has entered into a licensing agreement with Eli Lilly and…
